U.S. & HIV

Pediatric HIV and related issues should remain a priority for the domestic HIV response

Domestic Epidemic

New HIV infections in children in the United States have dramatically declined since the beginning of the epidemic—infections in children peaked in 1992 when there were approximately 2,000 new pediatric HIV cases per year. Today there are only about 100-200 new infections in children each year. EGPAF advocates to ensure that new infections in children remain low and that pregnant women and children infected with HIV have access to the critical services and medicines they need to survive and thrive. Read More

NIH Research

Since its inception, EGPAF has advocated for children to be included in and benefit from scientific advances in HIV treatment and prevention. The National Institute of Health (NIH) is the worldwide leader in HIV research and its work to combat pediatric HIV and AIDS is crucial to ensuring that children impacted by the disease survive and thrive. EGPAF regularly engages with NIH to keep pediatric AIDS research a priority and pushes Congress to sufficiently fund promising HIV research. Read EGPAF CEO’s letter advocating for the important work of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network.

Ryan White HIV/AIDS Program

The Ryan White HIV/AIDS Program provides critical services to women and children impacted by HIV in the United States, particularly for the approximately 8,500 HIV positive pregnant women each year who need tailored care to ensure HIV is not transmitted to their children. This is why the Foundation continues to advocate for Ryan White programs as a critical part of the U.S. HIV service continuum, particularly supporting Ryan White Part D which addresses the medical and non-medical needs of women, infants, children, youth and families living with and impacted by HIV and AIDS.

Pediatric Drug and Device Development

Children are not just small adults, and children being treated for HIV, or any disease, should have drugs that are labeled and formulated specifically for them.  EGPAF works with Congress and the Food and Drug Administration (FDA) on pediatric drug laws and programs to ensure that new medicines, vaccines and devices take into account the unique needs of children.